BUZZ-PREVIEW-India's Dr Reddy's falls ahead of Q3 results

Dr Reddy's Laboratories REDY.NS drops ~1% to 1,281.90 rupees ahead of Q3 results

Drugmaker had reported 9.5% drop in Q2 profit, while rev grew ~17%

On avg, analysts see REDY's Q3 consol net profit growing ~8% y/y and rev rising 12%, per data compiled by LSEG

Expects "subdued" U.S. sales growth on lower sales of cancer drug gRevlimid

However, BNP Paribas says gains from nicotine replacement therapy, which REDY bought from Haleon HLN.L for $633 mln in 2024, will help rev

Centrum says sales of vaccines that co acquired via partnership with French drugmaker Sanofi's SASY.PA Indian unit last year will help India rev

Rivals Cipla CIPL.NS and Sun Pharma SUN.NS will report Q3 results next week

REDY's ~20% YTD climb in 2024 was the smallest vs CIPL's ~23% rise and SUN's ~50% jump